MaxCyte [MXCT] vs Stryker [SYK] Detailed Stock Comparison

MaxCyte Inc.

NASDAQ
Loading...

Stryker Corporation

NYSE
Loading...

TLDR: Quick Comparison Summary

Based on 21 vital metrics comparison: MaxCyte Inc. wins in 6 metrics, Stryker Corporation wins in 13 metrics, with 0 ties. Stryker Corporation appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric MaxCyte Inc. Stryker Corporation Better
P/E Ratio (TTM) -2.07 39.21 Stryker Corporation
Price-to-Book Ratio 0.55 5.62 MaxCyte Inc.
Debt-to-Equity Ratio 10.46 72.97 MaxCyte Inc.
PEG Ratio 0.21 0.72 MaxCyte Inc.
EV/EBITDA -0.20 19.90 Stryker Corporation
Profit Margin (TTM) -135.14% 12.92% Stryker Corporation
Operating Margin (TTM) -94.81% 27.24% Stryker Corporation
EBITDA Margin (TTM) N/A 27.24% N/A
Return on Equity -23.63% 15.08% Stryker Corporation
Return on Assets (TTM) -12.60% 7.92% Stryker Corporation
Free Cash Flow (TTM) $-36.18M $4.28B Stryker Corporation
Dividend Yield N/A 0.97% N/A
1-Year Return -49.09% -17.25% Stryker Corporation
Price-to-Sales Ratio (TTM) 2.88 5.02 MaxCyte Inc.
Enterprise Value $7.89M $138.30B Stryker Corporation
EV/Revenue Ratio 0.24 5.51 MaxCyte Inc.
Gross Profit Margin (TTM) 77.95% 64.54% MaxCyte Inc.
Revenue per Share (TTM) $0 $66 Stryker Corporation
Earnings per Share (Diluted) $-0.42 $8.40 Stryker Corporation
Beta (Stock Volatility) 1.45 0.93 Stryker Corporation
Short % of Float 5.23% 1.20% Stryker Corporation

MaxCyte Inc. vs Stryker Corporation Stock Performance Analysis

Loading Price Chart...

MXCT
SYK

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
MaxCyte Inc.3.57%0.87%11.54%43.21%-22.15%-25.16%
Stryker Corporation-1.36%2.13%0.38%-11.91%-13.33%-11.56%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
MaxCyte Inc.-49.09%-77.10%-93.41%-93.41%-93.41%-93.41%
Stryker Corporation-17.25%6.06%22.47%172.95%440.98%592.85%

Performance & Financial Health Analysis: MaxCyte Inc. vs Stryker Corporation

MetricMXCTSYK
Market Information
Market Cap i$92.07M$126.25B
Market Cap CategoryMicro capLarge cap
10 Day Avg. Volume i734,6961,881,406
90 Day Avg. Volume i895,7592,161,139
Last Close$1.16$307.94
52 Week Range$0.64 - $2.37$281.00 - $404.87
% from 52W High-51.05%-23.94%
All-Time High$17.44 (Jul 26, 2021)$406.19 (Jan 27, 2025)
% from All-Time High-93.35%-24.19%
Growth Metrics
Quarterly Revenue Growth-0.16%0.11%
Quarterly Earnings Growth-0.16%0.56%
Financial Health
Profit Margin (TTM) i-1.35%0.13%
Operating Margin (TTM) i-0.95%0.27%
Return on Equity (TTM) i-0.24%0.15%
Debt to Equity (MRQ) i10.4672.97
Cash & Liquidity
Book Value per Share (MRQ)$1.61$58.61
Cash per Share (MRQ)$0.96$10.71
Operating Cash Flow (TTM) i$-34,410,000$5.04B
Levered Free Cash Flow (TTM) i$-15,469,750$4.17B
Dividends
Last 12-Month Dividend Yield iN/A0.97%
Last 12-Month Dividend iN/A$3.40

Valuation & Enterprise Metrics Analysis: MaxCyte Inc. vs Stryker Corporation

MetricMXCT (Apr 24, 2026)SYK (Apr 24, 2026)
Price Ratios
P/E Ratio (TTM) i-2.0739.21
Forward P/E i-3.3319.67
PEG Ratio i0.210.72
Price to Sales (TTM) i2.885.02
Price to Book (MRQ) i0.555.62
Market Capitalization
Market Capitalization i$92.07M$126.25B
Enterprise Value i$7.89M$138.30B
Enterprise Value Metrics
Enterprise to Revenue i0.245.51
Enterprise to EBITDA i-0.2019.90
Risk & Other Metrics
Beta i1.450.93
Book Value per Share (MRQ) i$1.61$58.61

Financial Statements Comparison: MaxCyte Inc. vs Stryker Corporation

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricMXCT (2025)SYK (2025)
Revenue/Sales i33.03M25.12B
Cost of Goods Sold i6.22M9.05B
COGS % of Revenue i18.8%36.0%
Gross Profit i26.80M16.07B
Gross Margin i81.2%64.0%
Research & Development i20.82M1.62B
Operating Income (EBIT) i-45.29M5.06B
Operating Margin i-137.1%20.1%
EBITDA i-33.53M6.48B
EBITDA Margin i-101.5%25.8%
Pre-Tax Income i-44.63M4.51B
Pre-Tax Income % of Revenue i-135.1%18.0%
Income Tax i01.27B
Income Tax % of Revenue i0.0%5.0%
Net Income (Profit) i-44.63M3.25B
Profit Margin i-135.1%12.9%

Balance Sheet & Liquidity Metrics

MetricMXCT (2025)SYK (2025)
Cash & Equivalents i20.07M4.01B
Total Current Assets i118.37M14.76B
Total Current Assets % of Revenue i358.4%58.7%
Total Current Liabilities i14.27M7.79B
Total Current Liabilities % of Revenue i43.2%31.0%
Long-Term Debt i16.49M14.86B
Long-Term Debt % of Revenue i49.9%59.2%
Total Shareholders Equity i171.49M22.42B
Retained Earnings i-261.48M20.47B
Retained Earnings % of Revenue i-791.7%81.5%
Property, Plant & Equipment i12.84M1.79B

Cash Flow Statement Comparison

MetricMXCT (2025)SYK (2025)
Operating Cash Flow i-35.79M4.70B
Operating Cash Flow % of Revenue i-108.4%18.7%
Capital Expenditures i-1.77M-761.00M
Free Cash Flow i-36.18M4.28B
FCF Margin i-109.5%17.1%
Debt Repayment iN/A-1.40B
Common Stock Repurchase iN/AN/A

Short Interest & Institutional Ownership Analysis

MetricMXCTSYK
Shares Short i5.55M4.42M
Short Ratio i5.361.95
Short % of Float i5.23%1.20%
Shares Outstanding i106.79M382.50M
Float Shares i105.71M346.55M
% Held by Insiders i1.40%5.37%
% Held by Institutions i65.81%82.09%
% Held by Public i32.79%12.54%

Dividend Analysis & Yield Comparison: MaxCyte Inc. vs Stryker Corporation

MetricMXCTSYK
Last 12-Month Dividend iN/A$3.40
Last 12-Month Dividend Yield iN/A0.97%
3-Year Avg Annual Dividend iN/A$3.23
3-Year Avg Dividend Yield iN/A0.24%
3-Year Total Dividends iN/A$9.69
Ex-Dividend DateN/ADec 31, 2025